Liminatus Pharma, Inc. Class A Common Stock (LIMN) NASDAQ
0.19
+0.0073(+4.06%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Liminatus Pharma, Inc. Class A Common Stock
Address
6 Centerpointe Drive
La Palma, CA 90623
United States of America (the)
Phone
213 273 5453
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3
First IPO Date
May 01, 2025
Key Executives
| Name | Title | Pay | Year Born |
| Chris Kim | CEO & Chairman | 0 | 1960 |
| Beom Kyu Choi | Chief Technology Officer & Member of Scientific Advisory Board | 0 | 1972 |
| Byong Chul Yoo | Chief Science Officer & Member of Scientific Advisory Board | 0 | 1972 |
| Sang-jin Lee | Head of Research & Development and Member of Scientific Advisory Board | 0 | 1968 |
| Scott Dam | Chief Financial Officer | 0 | 1979 |
Description
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.
